{
  "paper": {
    "title": "SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade",
    "doi": "10.1038/s41586-025-09006-8",
    "publication_year": 2025,
    "domain": "oncology-immunology",
    "study_type": "preclinical+retrospective"
  },
  "core_question": "The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.",
  "datasets_or_cohorts": [
    {
      "id": "mouse-efficacy",
      "label": "Mouse Efficacy Cohort",
      "sample_size_or_observations": "78",
      "description": "78 tumor-bearing mice pooled across repeat experiments for combination therapy (intratumoral mRNA vaccine and anti-PD-L1)."
    },
    {
      "id": "mouse-control",
      "label": "Mouse Control Cohort",
      "sample_size_or_observations": "84",
      "description": "84 tumor-bearing mice pooled across matched controls (vaccine only, ICI only, and vehicle)."
    },
    {
      "id": "human-vaccinated",
      "label": "Human Vaccinated Subgroup",
      "sample_size_or_observations": "43",
      "description": "Retrospective cohort of metastatic patients (43 total) who received prior SARS-CoV-2 mRNA vaccination before ICI treatment."
    },
    {
      "id": "human-unvaccinated",
      "label": "Human Unvaccinated Subgroup",
      "sample_size_or_observations": "87",
      "description": "Retrospective cohort of metastatic patients (87 total) who did not receive prior SARS-CoV-2 mRNA vaccination before ICI treatment."
    }
  ],
  "major_limitations": [
    "The human analysis is retrospective and non-randomized; residual confounding is likely.",
    "Vaccination timing relative to ICI initiation varied across patients.",
    "Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.",
    "Mouse model effects may not map one-to-one to all human tumors."
  ]
}